Proud to be part of this great team led by @bradspellberg.bsky.social
🔥Our LTE is now published
“Evidence Over Eminence: Rethinking Specialty Guidelines Amid the ATS–IDSA Debate.”
A timely discussion on evidence vs eminence in the guidelines development. #IDsky
academic.oup.com/cid/article/...
Ending mandatory #influenza #vaccine is a HUGE mistake
The 1918–1919 flu pandemic tore through military camps and frontline soldiers, weakening readiness when it mattered most.
Infectious diseases are a force readiness issue, not just an individual one.
www.washingtonpost.com/national-sec...
In honor of this post @dralicehan.bsky.social
bsky.app/profile/ppid...
A sort of cute drawing of a badger and some zoonoses associated with them
Everything is a zoonosis! Drawing/listing challenge.
#40- Badger
Requested by @jonathanrydermd.bsky.social
I drew an American badger (Taxidea taxus) but found some heated stories re: Great British Badger Debate (Meles meles) related to their role in bovine TB
Thoughts friends in 🇬🇧?
#IDSky #VetSky
We (@drmichaelmarks.bsky.social included) did a bit of a thought experiment for how to do this for a syndromic disease, but even this was challenging for a lot of reasons (and it uses a composite DOOR which you will probably hate lol)
www.sciencedirect.com/science/arti...
Its a good point, although honestly even with rapid BCx ID, earliest you KNOW its Staph aureus is time to positive (8-24 hours), which may or may not miss the window. "Looking" gram positive is really hard to guess and doubt NNT with empiric clinda would be beneficial anyway
Might just be random chance since its a sub-group analysis. Diarrhea more common in clinda definitely makes sense!
In SNAP Clindamycin
Persistent bactremia was more in Clindamycin group
It's intriguing!
Any thoughts, insights please
#ESCMIDGlobal2026 #idsky
I’m sad that we don’t have a new treatment for SAB but I’m also glad it’s not clinda
🔥 Late Breakers
SNAP platform RCT| Adjunctive Clindamycin in S.aureus bacteraemia
❌ No mortality benefit
90d mortality:16.9% vs 15.2% aOR 1.16 (CrI cross 1)
📊PPSup(~7%)→Futility threshold reached
⚠️ICU subgp:numerically worse with clinda
⚖️CDAD:no # (~2%)😯
#ESCMIDGlobal2026 #idsky
Lots of cool trials reporting at #ESCMIDGlobal2026
OCTOPUS - low dose CT better than CXR (and US) to diagnose pneumonia in older adults
SNAP - adjunctive clinda in SAB doesn't help, may harm. Interestingly, no excess C diff
PROCALBAN - daily POC PCT -> safe, big reductions in Abx duration in LMIC
🚨 Late Breaker – PROCALBAN OL RCT
🧪 PCT-guided de-escalation in sepsis (Bangladesh,n=532)
🎯Daily PCT→ stop Abx after 72h if <0.5 or ↓>80%
⏱️ Antibiotic duration nearly halved
• 4.7 vs 9d(p<0.0001)
🛡️ Safety preserved
• ⚰️ No difference in 28d mortality
#ESCMIDGlobal2026 #idsky
Don't be shy to take on a little two-week side project. These five months will be the most precious three years of your academic journey.
Absolutely! Often re-watches may fill in gaps that others didn't cover!
I definitely miss a few people in ID who have decided to exclusively post on X or primarily post on X. But platform wise, BlueSky is much more favorable for quality of life (no ads, more scientifically focused, algorithm less biased albeit not useful generally). We have a good crew here I think
▶️💥Tick tock, AMR clock: how should I treat my next ESBL bacteraemia patient?
Excellent talk by Prof Tong
Carbapenem sparing drug? Do we need it? Data? Does it increase CRE?
Bayesian priori
Next patient with ESBL : would you give pip tazo or Mero ?
#ESCMIDGlobal2026 @steventong.bsky.social 👏 #idsky
🔥 💥Late-Breakers |COBRA RCT
1-day of antibiotic treatment after adequate endoscopic biliary drainage is non-inferior to 4-7 days in adults with acute cholangitis.
💡 Shorter is better+source control
Practice-changing? #ESCMIDGlobal2026 #idsky
Whoohoo! Guess what? Our IDSA Private Practice Community of Practice website landing page is up! 🥰
Thank you to everyone who joined our webinar this morning 🙏.
In case you missed it, you can find it on our new website page 👇
www.idsociety.org/membership-c...
This is really wild lol. Can you put it on 0.5 speed so you can get twice as much credit? Lol
▶️💥When the fairy dust settles: critical appraisal of presented trials
Excellent talk by Prof.HUTTNER @angelahuttner.bsky.social
How did PeterPen replicate the MERINO trial?
Co-intervention bias?
Are you going forward to 1000 patients for 30d mortality?
Did you get FUBC?
🌟7d? #ESCMIDGlobal2026
Superb session at #ESCMIDGlobal2026 on the PeterPen and ASTARTE trials
Important results, great discussion, thanks to @angelahuttner.bsky.social and friends
Big remaining evidence gap concerns optimal empiric (rather than follow on) therapy
ACORN study strategy with consent waiver may work
Thanks so much for sharing your talk! Amazing how much science has been done in this space, but also how much more there is to learn
SUMMARY:
Here’s a thread on the talk I gave at #ESCMIDGlobal 2026:
“Toilets: Flushing and Spread of Pathogens” — nicknamed “You can’t outrun the plume.” Using published studies, I covered the key components shown below. There’s a surprising amount of data, but still a lack of high-quality intervention trials
Late-breaking #Lancet SCOUT RCT results at #ESCMIDGlobal2026:
💊 Day 7 clinical resolution
• Nitrofurantoin: 74%
• Pivmecillinam: 70%
• Fosfomycin (2 doses): 67%
• Fosfomycin (single dose): 59%
🔑 single-dose fosfomycin underperforms vs standard short-course regimens
Research in context panel for a paper published in The Lancet, entitled "Clinical and bacteriological effectiveness of three different short-course antibiotic regimens and single-dose fosfomycin for uncomplicated lower urinary tract infections in women (SCOUT): a pragmatic, multicentre, open-label, randomised clinical trial". Copyright: 2026 Elsevier Ltd. All rights reserved.
A new study, presented at @escmid.bsky.social, found that Nitrofurantoin was the most effective treatment and single-dose fosfomycin the least effective treatment for uncomplicated urinary tract infections.
Explore the research 👉 spkl.io/63320A4Yui #ESCMIDGlobal2026 #ESCMID
Study: 14 stewards at 10 US hospitals. 50% struggled to ID discharge pts for audit-feedback. Strong provider ties & existing initiatives aided success. ID consults eased guidance. 🏥🔍💊
Kick off day 4 of #ESCMIDGlobal2026 with a deep dive into the latest advances in #sepsis care and what they mean for clinical practice.
Explore emerging evidence, new approaches and their real-world implications as the field continues to evolve - don’t miss out!
My first #ESCMIDGlobal2026 session on Monday is Interconnected microbiomes and resistomes across One Health. The first speaker is Amy Mathers with Hospital microbiomes as hotspots for emerging resistance: surveillance-to-intervention
This was awesome! Thanks for sharing